NexGel, Inc. (NXGL) 2025 Annual Report Summary
Business Context and Reporting Period
This summary covers the Annual Report on Form 10-K for NexGel, Inc. for the fiscal year ended December 31, 2025. NexGel is a Delaware corporation specializing in the manufacturing of high-water content, electron beam cross-linked hydrogels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company operates through four primary lines of business: Contract Manufacturing, Custom & White Label, Consumer Branded Products (including MedaGel, Kenkoderm, and Silly George), and Medical Devices. The company is classified as a "smaller reporting company" and an "emerging growth company."
Key Financial Metrics
| Metric ($ in thousands) | 2025 | 2024 |
|---|---|---|
| Revenues, Net | $11,421 | $8,688 |
| Gross Profit | $4,509 | $2,748 |
| Gross Margin | 39.5% | 31.6% |
| Operating Loss | $(3,352) | $(3,554) |
| Net Loss (Attributable to NexGel) | $(3,000) | $(3,281) |
| Net Cash Used in Operating Activities | $(1,311) | $(3,867) |
| Cash and Cash Equivalents (End of Period) | $317 | $1,807 |
| Restricted Cash | $741 | $0 |
| Working Capital | $1,382 | $2,644 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased by 31.5% to $11.4 million, driven primarily by the full-year contribution of the "Silly George" beauty brand acquired in May 2024 and growth in branded consumer products.
- Cost of Revenues: Increased 16.4% to $6.9 million, aligning with higher sales volume and the inclusion of Silly George inventory costs.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 26.3% to $7.9 million due to increased compensation, advertising, and professional fees. Research and development expenses decreased significantly to $2 thousand from $78 thousand.
- Liquidity: Cash and cash equivalents declined to $317 thousand from $1.8 million. However, the company holds $741 thousand in restricted cash related to a partnership advance from STADA Arzneimittel AG.
- Segment Performance: The NexGel segment reported an operating loss of $3.6 million, while the CG Labs joint venture segment reported an operating profit of $275 thousand.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The company has incurred recurring losses and negative cash flows. Management states that current cash resources are insufficient to meet plans for the next twelve months, raising substantial doubt about the ability to continue as a going concern. Future operations depend on raising additional capital.
- Capital Raises: The company raised $963 thousand via a rights offering in August 2025. In a subsequent event (February 2026), the company entered an agreement for a convertible note facility up to $56.7 million to fund an approved acquisition.
- Strategic Acquisitions: In March 2026, NexGel entered an agreement to acquire a commercial-stage biomaterials portfolio from Celularity Inc. for up to $35 million, contingent on financing.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding the lack of segregation of duties and "super user" access in the accounting department.
- Risks: Key risks include reliance on Amazon and Shopify for sales, dependence on single-source suppliers for raw materials, and the need for strategic partnerships to commercialize medical devices.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $317k unrestricted cash balance against the stated need for additional capital to fund operations for the next 12 months.
- Subsequent Financing: Confirm the status and closing of the $56.7 million convertible note facility and the $35 million Celularity acquisition announced in early 2026.
- Restricted Cash: Review the terms of the $741k restricted cash advance from STADA to understand usage limitations and repayment obligations.
- Internal Controls: Monitor the remediation plan for material weaknesses in financial reporting, specifically regarding journal entry approvals and user access rights.
- Revenue Concentration: Assess the impact of the Silly George acquisition on future revenue stability, noting that no single customer accounted for 10% of revenue in 2025.